These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 604139)

  • 1. Field study with a live influenza vaccine (RIT 4050) in children.
    Kunz C; Hofmann H
    Dev Biol Stand; 1977 Jun 1-3; 39():93-7. PubMed ID: 604139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
    Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of 2 influenza vaccine schedules in 6- to 23-month-old children.
    Englund JA; Walter EB; Fairchok MP; Monto AS; Neuzil KM
    Pediatrics; 2005 Apr; 115(4):1039-47. PubMed ID: 15805382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Local and systemic antibody response after vaccination with 3 different types of vaccines against influenza I. Hemagglutinationinhibiting antibodies (author's transl)].
    Kuwert EK; Werner J; Scheiermann N; Pledt T
    Zentralbl Bakteriol Orig A; 1979 Jul; 244(2-3):155-74. PubMed ID: 506543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and safety of intradermal influenza immunization at a reduced dose in healthy children.
    Chiu SS; Peiris JS; Chan KH; Wong WH; Lau YL
    Pediatrics; 2007 Jun; 119(6):1076-82. PubMed ID: 17545373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age.
    Block SL; Yogev R; Hayden FG; Ambrose CS; Zeng W; Walker RE
    Vaccine; 2008 Sep; 26(38):4940-6. PubMed ID: 18662737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children.
    Neuzil KM; Jackson LA; Nelson J; Klimov A; Cox N; Bridges CB; Dunn J; DeStefano F; Shay D
    J Infect Dis; 2006 Oct; 194(8):1032-9. PubMed ID: 16991077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparative study on safety and immunogenicity between influenza subunit vaccine and split vaccine].
    Dong PM; Li YQ; Zheng TZ; Jia YP; Li F; Han TW; Qiao RX; Zhang BH
    Zhonghua Liu Xing Bing Xue Za Zhi; 2003 Jul; 24(7):570-3. PubMed ID: 12975010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody response after measles immunization.
    Ariyasriwatana C; Kalayanarooj S; Pattamadilok S
    J Med Assoc Thai; 2003 Aug; 86 Suppl 3():S701-6. PubMed ID: 14700170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 5-year follow-up of antibody response in children vaccinated with single dose of live attenuated SA14-14-2 Japanese encephalitis vaccine: immunogenicity and anamnestic responses.
    Sohn YM; Tandan JB; Yoksan S; Ji M; Ohrr H
    Vaccine; 2008 Mar; 26(13):1638-43. PubMed ID: 18294743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody response to a two-dose regimen of influenza vaccine in allogeneic T cell-depleted and autologous BMT recipients.
    Engelhard D; Nagler A; Hardan I; Morag A; Aker M; Baciu H; Strauss N; Parag G; Naparstek E; Ravid Z
    Bone Marrow Transplant; 1993 Jan; 11(1):1-5. PubMed ID: 8431706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
    Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR;
    Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of the immune response to trivalent split influenza vaccine in children with solid tumors.
    Bektas O; Karadeniz C; Oguz A; Berberoglu S; Yilmaz N; Citak C
    Pediatr Blood Cancer; 2007 Dec; 49(7):914-7. PubMed ID: 17262793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia.
    Concha A; Giraldo A; Castañeda E; Martínez M; de la Hoz F; Rivas F; Depetris A; Svennerholm AM; Sack DA
    Bull Pan Am Health Organ; 1995 Dec; 29(4):312-21. PubMed ID: 8605522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum and mucosal immunologic responses in children following the administration of a new inactivated intranasal anti-influenza vaccine.
    Greenbaum E; Furst A; Kiderman A; Stewart B; Levy R; Schlesinger M; Morag A; Zakay-Rones Z
    J Med Virol; 2001 Sep; 65(1):178-84. PubMed ID: 11505461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant.
    Goji NA; Nolan C; Hill H; Wolff M; Noah DL; Williams TB; Rowe T; Treanor JJ
    J Infect Dis; 2008 Sep; 198(5):635-41. PubMed ID: 18694338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of 1 and 2 doses of live attenuated influenza vaccine in vaccine-naive children.
    Bracco Neto H; Farhat CK; Tregnaghi MW; Madhi SA; Razmpour A; Palladino G; Small MG; Gruber WC; Forrest BD;
    Pediatr Infect Dis J; 2009 May; 28(5):365-71. PubMed ID: 19395948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and safety of low dose virosomal adjuvanted influenza vaccine administered intradermally compared to intramuscular full dose administration.
    Künzi V; Klap JM; Seiberling MK; Herzog C; Hartmann K; Kürsteiner O; Kompier R; Grimaldi R; Goudsmit J
    Vaccine; 2009 Jun; 27(27):3561-7. PubMed ID: 19464535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical evaluation of neuraminidase monospecific (HEqN2) recombinant influenza vaccine in children.
    Beutner KR; Rizzone C; DeMello S; Ogra PL
    Dev Biol Stand; 1976; 33():162-70. PubMed ID: 782964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Half- vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses.
    Engler RJ; Nelson MR; Klote MM; VanRaden MJ; Huang CY; Cox NJ; Klimov A; Keitel WA; Nichol KL; Carr WW; Treanor JJ;
    Arch Intern Med; 2008 Dec; 168(22):2405-14. PubMed ID: 19064822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.